Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2026-04-14 @ 8:15 AM
Study NCT ID:
NCT02459002
Status:
COMPLETED
Last Update Posted:
2023-03-15
First Post:
2015-05-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Prospective Study to Determine Impact of Early Palliative Care Consult on Quality of Life (QOL), Cancer Related Symptoms In Advanced Lung Cancer Patients: Thoracic Pilot Project
Sponsor:
M.D. Anderson Cancer Center
Organization:
Study Overview
Official Title:
Prospective Study to Determine Impact of Early Palliative Care Consult on Quality of Life (QOL), Cancer Related Symptoms In Advanced Lung Cancer Patients
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to learn about the quality of life (QOL) in participants with advanced lung cancer.
Detailed Description:
Advanced lung cancer (ALC) will be assessed for participant outcomes in a sample which is prior initiation of palliative consultation and in a sample after the initiation of early palliative consultation.
Study goals are:
I. To determine the differences in participant outcomes including quality of life (QOL); symptom distress \[Edmonton symptom assessment scale (ESAS)\] and caregiver outcomes \[Zarit Burden Interview {ZBI}, Hospital Anxiety and Depression scale(HADS) and FAMCARE\] at week 12 in advanced lung cancer (ALC) patients receiving early palliative care consultation versus those who don't.
II. Identify the cellular, molecular, and immune basis for the development of symptoms in patients with ALC.
Study goals are:
I. To determine the differences in participant outcomes including quality of life (QOL); symptom distress \[Edmonton symptom assessment scale (ESAS)\] and caregiver outcomes \[Zarit Burden Interview {ZBI}, Hospital Anxiety and Depression scale(HADS) and FAMCARE\] at week 12 in advanced lung cancer (ALC) patients receiving early palliative care consultation versus those who don't.
II. Identify the cellular, molecular, and immune basis for the development of symptoms in patients with ALC.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| NCI-2019-02352 | REGISTRY | CTRP (Clinical Trial Reporting Program) | View |